Then, mutations were found also in the spliceosome genes SF3B1 and SRSF2 of 42% of MDS patients, and these splicing factors were significantly linked to the various clinical manifestations of MDS [154,155,160]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.